Arrowhead CEO cites slow commercial ramp for Redemplos
Arrowhead Pharmaceuticals CEO Chris Anzalone said the company is transitioning from development to commercialization, with its first RNA-interference drug now on the market and more than 20 other candidates in testing. He characterized the launch as a slow burn toward an estimated peak sales range.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.